Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A
Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined by excessive hepatic lipid accumulation. This study evaluated the therapeutic effects and molecular mechanisms of tirzepatide, a dual GIP and GLP-1 receptor agonist, in treating hepatic steatosis. Eight-week-old C57BL/6J mic...
Saved in:
| Main Authors: | Yun Li, Wencong Sun, Hong Liu, Xiong Z. Ruan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2025-11-01
|
| Series: | Genes and Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352304225002508 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Novel Dual GIP and GLP‐1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism
by: Yikai Zhang, et al.
Published: (2025-05-01) -
Efficacy of Tirzepatide Dual GIP/GLP‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched Study
by: Ahmed Y. Azzam, et al.
Published: (2025-03-01) -
Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01) -
Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide
by: Zsombor I. Hegedűs, et al.
Published: (2025-06-01) -
Effect of tirzepatide-induced weight loss on adipose tissue in obesity: rationale and design of the randomized placebo-controlled Tirzepatide Brown and Beige Adipose Tissue Activation (TABFAT) trial
by: Rok Herman, et al.
Published: (2025-08-01)